Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have received an average rating of “Moderate Buy” from the seven research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $18.29.

A number of research analysts have commented on the stock. Barclays increased their price target on shares of Elanco Animal Health from $19.00 to $23.00 and gave the company an “overweight” rating in a research report on Thursday, May 9th. Morgan Stanley increased their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Piper Sandler reiterated a “neutral” rating and set a $19.00 price target (up from $18.00) on shares of Elanco Animal Health in a research report on Monday, May 13th. Finally, The Goldman Sachs Group increased their price target on shares of Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a research report on Tuesday, February 27th.

Insider Transactions at Elanco Animal Health

In other news, Director William F. Doyle bought 15,000 shares of the company’s stock in a transaction dated Tuesday, May 21st. The stock was bought at an average cost of $16.98 per share, for a total transaction of $254,700.00. Following the completion of the acquisition, the director now owns 76,330 shares in the company, valued at approximately $1,296,083.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.57% of the stock is currently owned by company insiders.

Institutional Trading of Elanco Animal Health

A number of institutional investors have recently modified their holdings of ELAN. UBS Group AG lifted its holdings in Elanco Animal Health by 78.2% in the third quarter. UBS Group AG now owns 681,905 shares of the company’s stock worth $7,665,000 after buying an additional 299,166 shares during the period. Acadian Asset Management LLC purchased a new stake in Elanco Animal Health in the third quarter worth about $95,000. Dark Forest Capital Management LP lifted its holdings in Elanco Animal Health by 80.3% in the third quarter. Dark Forest Capital Management LP now owns 35,779 shares of the company’s stock worth $402,000 after buying an additional 15,930 shares during the period. Stifel Financial Corp lifted its holdings in Elanco Animal Health by 64.6% in the third quarter. Stifel Financial Corp now owns 185,453 shares of the company’s stock worth $2,084,000 after buying an additional 72,814 shares during the period. Finally, Federated Hermes Inc. lifted its holdings in Elanco Animal Health by 0.6% in the third quarter. Federated Hermes Inc. now owns 2,051,833 shares of the company’s stock worth $23,063,000 after buying an additional 11,846 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Trading Down 0.8 %

Shares of ELAN opened at $18.05 on Monday. The firm’s 50 day simple moving average is $16.13 and its 200 day simple moving average is $15.58. The company has a market capitalization of $8.92 billion, a P/E ratio of -6.81, a P/E/G ratio of 1.76 and a beta of 1.45. The company has a debt-to-equity ratio of 0.95, a current ratio of 3.29 and a quick ratio of 1.96. Elanco Animal Health has a 1-year low of $8.52 and a 1-year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.08. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. Elanco Animal Health’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period last year, the firm posted $0.45 earnings per share. Sell-side analysts forecast that Elanco Animal Health will post 0.93 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.